Market news, stock analysis and investing ideas

Pre-Market Movers: CG Oncology Jumps on Phase 3 Win, Telus on Québecor Approach

CG Oncology rose 32.39% and Telus 22.04% in Monday's pre-market, while Global Mofy AI more than quintupled on a thin float. Summit Therapeutics announced an FDA complete response letter on Sunday.

Health Care sector
Photo: Pexels

CG Oncology, Telus and Global Mofy AI led pre-market trading on Monday, Nov. 16, after a Phase 3 bladder cancer result, an unsolicited takeover proposal and an AI-linked investment disclosure. Summit Therapeutics said on Sunday that the FDA issued a complete response letter on its lung cancer drug. Pre-market is trading before the 9:30 a.m. ET open, when volume is thin.

Company announcements drove the moves, and every leader sits below its early high

Most of the big pre-market moves trace to a single company announcement. CG Oncology (market value about $6.65 billion) and Telus (about $19.3 billion) are large enough that their moves carry weight, and both have pulled back from their pre-market highs. The sharpest percentage gains, Global Mofy AI and Highway Holdings, came on floats (the shares available to trade) of about 9.53 million and 2.96 million shares.

CG Oncology: Phase 3 result and a filing timeline

CG Oncology (CGON) traded at $98.50 at 9:00 a.m. ET, up 32.39% from Friday's close of $74.40, with a pre-market high of $107.58. At 8:03 a.m. ET the company said its Phase 3 PIVOT-006 trial of cretostimogene in bladder cancer met its primary endpoint, cutting the risk of recurrence by 68% against control. It called the safety profile "compelling."

At 8:21 a.m. ET it said it plans to complete a biologics license application (BLA, the request for FDA approval) for BCG-unresponsive non-muscle-invasive bladder cancer in March 2027. A second BLA, for intermediate-risk Ta disease, is planned for the second quarter of 2027.

Pre-market volume of 352,339 shares is small against an average of about 1.58 million a day, so the open is the first broad test of demand. The results are topline. It is not clear when the climb began relative to the 8:03 a.m. announcement.

Telus: a non-binding approach from Québecor

Telus (TU) traded at $10.41 in pre-market, up 22.04% from Friday's close of $8.53, after touching $11.98. At 7:36 a.m. ET the company said its board had received an unsolicited, non-binding and conditional acquisition proposal from Québecor and had formed a special committee to evaluate it. It is not clear what price Québecor has in mind.

Volume was 2.83 million shares by 9:00 a.m. ET, against a 10-day average of about 7.08 million. The stock has given back part of its early spike.

Global Mofy AI: a spike on indirect Anthropic exposure

Global Mofy AI (GMM) traded at $4.83, up 373.46% from Friday's close of $1.02, in a range of $0.98 to $6.11. At 8:32 a.m. ET the company said it made an indirect investment in Anthropic through a fund in September 2026. The size of the investment is not clear.

About 35.69 million shares changed hands, against a 10-day average of 231,395. The company has a market value of about $9.9 million. It is not clear whether the surge began before the 8:32 a.m. announcement.

Highway Holdings' dividend and Lexeo's trial update

Highway Holdings (HIHO) rose 28.66% from Friday's after-hours close of $0.80 to $1.03, in a range of $0.80 to $1.19. At 7:00 a.m. ET it declared a special cash dividend of US$0.43228 per share, payable Nov. 30. Volume was 39.16 million shares against a 10-day average of 55,868, so the float turned over about 13 times.

Shares normally adjust lower by about the dividend amount on the ex-dividend date, the first day new buyers do not receive the payout.

Lexeo Therapeutics (LXEO) traded at $3.42, up 19.24% from Friday's close of $2.87, with a high of $4.30. The company paired its third-quarter report with an update on the HEROIC-PKP2 trial of LX2020. It is not clear which part of the update drove the move. Volume was 9.25 million shares against a 10-day average of about 1.15 million.

Summit Therapeutics gets an FDA complete response letter

Summit Therapeutics (SMMT) said on Sunday, Nov. 15, that the FDA issued a complete response letter on its biologics license application for ivonescimab in lung cancer. Such a letter means the agency finished its review without approving the application in its current form. Friday's regular session closed before the news, so Monday is the first trading day since the announcement.

Deals, a debt offering and earnings before the open

  • Ameris Bancorp (ABCB) announced at 7:52 a.m. ET that it will acquire Bank of Central Florida. Target shareholders receive 0.6279 Ameris share for each of theirs, in a stock-only deal valued at $51.80 per Bank of Central Florida share.
  • Insight Enterprises (NSIT) said at 6:45 a.m. ET that it intends to offer $650.0 million of convertible senior notes due 2031, debt that can convert into shares, subject to market conditions.
  • GreenPower Motor (GP) rose 18.18% to $1.43 from Friday's after-hours close, well below a $2.77 high, on volume of 20.02 million shares. The cause is not clear.
  • Trading in WENN was halted for news from 8:25 a.m. ET and resumed at 9:00 a.m. ET; its units and warrants resumed at 9:05 a.m. ET. The announcement behind the halt is not clear.
  • XXII fell 24.04% from Friday's close to $0.585 after its report before the open. CYPH dropped 7.49% to $1.73 and PERI slipped 1.06% to $11.25.
  • Ballard Power Systems (BLDP) reported a third-quarter loss of $0.07 a share, wider than the 4-cent loss analysts had expected. Sales of $22.5 million were below analyst estimates, which varied.
  • Dawson Geophysical (DWSN) reported a third-quarter loss of $0.17 a share against $0.04 a year earlier, and sales of $11.4 million against $22.7 million.

Dates and open items

  • March 2027: CG Oncology plans to complete its first BLA.
  • Second quarter of 2027: CG Oncology plans a second BLA.
  • Nov. 30: Highway Holdings' special dividend is payable. The ex-dividend date is the one to know for the price adjustment.
  • Telus: a price or terms from Québecor, and the special committee's evaluation.
  • Summit Therapeutics: the reasons for the FDA letter and the company's plans to respond.
  • Insight Enterprises: final pricing of the convertible notes.
  • Global Mofy AI: the size of the fund investment.
  • Lexeo Therapeutics: the details of the HEROIC-PKP2 update.

Bottom line

CG Oncology's move follows trial data and a set filing timeline. Telus's follows a proposal that is non-binding and conditional. Global Mofy AI and Highway Holdings moved on very heavy turnover of small floats, and their pre-market prices come with little size behind them. Québecor's terms and the reasons for Summit's FDA letter are still open.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.